Valneva rises as chikungunya vaccine antibodies persist in 94% after five years
In short
The company experienced positive market movement following the release of extended data regarding its chikungunya shot. Test results showed that protective antibodies remained present in 94% of recipients five years post-vaccination. This demonstrated multi-year immune response highlights the long-term durability of the protection provided by the preventative immunization.
Key points
- The vast majority of recipients retain chikungunya antibodies half a decade after receivi…: The vast majority of recipients retain chikungunya antibodies half a decade after receiving the vaccine.
- Sustained immune responses over five years establish the long-term durability of the prev…: Sustained immune responses over five years establish the long-term durability of the preventive treatment.
- Positive clinical trial durability data prompted notable market gains for the pharmaceuti…: Positive clinical trial durability data prompted notable market gains for the pharmaceutical manufacturer.